Eosinophilic pneumonia natural history, complications, and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(3 intermediate revisions by one other user not shown)
Line 4: Line 4:


==Overview==
==Overview==
If left untreated, patients with eosinophilic pneumonia may progress to develop dyspnea, pleural effusion, and respiratory failure. Common complications of eosinophilic pneumonia include [[Respiratory failure|respiratory failure,]] [[relapse]], and [[Adverse effect (medicine)|adverse effects]] of [[Steroid|steroids]]. Prognosis is generally excellent, and only a couple of lethal cases have been reported.


==Natural History==
==Natural History==
 
If left untreated, patients with eosinophilic pneumonia may progress to develop dyspnea, pleural effusion, and respiratory failure.
==Complications==
==Complications==
* Chronic [[prednisone]] is associated with many side effects, including [[Immunosuppression|increased infections]], [[Bone fracture|weakened bones]], [[Peptic ulcer|stomach ulcers]], and changes in appearance.{{ref|Naughton}}
* [[Relapse]]: Relapses of ICEP are observed in up to 50% of patients. Relapses occur while tapering the dose of [[corticosteroids]] or after weaning.
* [[Respiratory failure]]: Only a couple of lethal cases have been reported.


== Prognosis ==
== Prognosis ==
Eosinophilic pneumonia due to cancer or parasitic infection carries a prognosis related to the underlying illness. AEP and CEP, however, have very little associated mortality as long as [[intensive care]] is available and treatment with corticosteroids is given. CEP often relapses when  [[prednisone]] is discontinued; therefore, some people with CEP require lifelong therapy. Chronic prednisone is associated with many side effects, including [[Immunosuppression|increased infections]], weakened bones, [[Peptic ulcer|stomach ulcers]], and changes in appearance.{{ref|Naughton}}
* Some patients with ICEP require lifelong therapy.<ref name="pmid12403693">{{cite journal| author=Philit F, Etienne-Mastroïanni B, Parrot A, Guérin C, Robert D, Cordier JF| title=Idiopathic acute eosinophilic pneumonia: a study of 22 patients. | journal=Am J Respir Crit Care Med | year= 2002 | volume= 166 | issue= 9 | pages= 1235-9 | pmid=12403693 | doi=10.1164/rccm.2112056 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12403693  }}</ref>
 
* Response to [[corticosteroid]] treatment is dramatic and treatment always leads to complete resolution, [[pulmonary function tests]] return to normal after recovery from the illness.<ref name="pmid12403693" />
Symptomatic and radiographic improvement is usually rapid and progressive with complete radiographic clearing over one to two months after initiation of systemic glucocorticoids [8].
* The [[pleural effusions]] may resolve more slowly than the [[Parenchyma|pulmonary parenchymal]] opacities.<ref name="pmid8982150">{{cite journal| author=Pope-Harman AL, Davis WB, Allen ED, Christoforidis AJ, Allen JN| title=Acute eosinophilic pneumonia. A summary of 15 cases and review of the literature. | journal=Medicine (Baltimore) | year= 1996 | volume= 75 | issue= 6 | pages= 334-42 | pmid=8982150 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8982150  }}</ref>
 
* [[Relapse|Relapses]] of ICEP are observed in up to 50% of patients and is usually associated with resumption of cigarette smoking after initial cessation.
Similarly, pulmonary function tests return to normal after recovery from the illness [8].
* These relapses occur while tapering the dose of [[corticosteroids]] or after weaning.<ref name="pmid22599359">{{cite journal| author=Rhee CK, Min KH, Yim NY, Lee JE, Lee NR, Chung MP et al.| title=Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia. | journal=Eur Respir J | year= 2013 | volume= 41 | issue= 2 | pages= 402-9 | pmid=22599359 | doi=10.1183/09031936.00221811 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22599359  }}</ref>
 
Relapse is uncommon and is usually associated with resumption of cigarette smoking after initial cessation [14,18-20].
 
The pleural effusions may resolve more slowly than the pulmonary parenchymal opacities [9].
 
Although response to corticosteroid treatment is dramatic
 
and treatment always leads to complete resolution,
 
relapses of ICEP are observed in up to 50% of patients [3].
 
These relapses occur while tapering the dose of corticosteroids
 
or after weaning. Relapses remain as responsive to
 
corticosteroids as the inaugural episode. Inhaled corticosteroids
 
have been proposed in order to prevent relapses
 
[7]. This is supported by a lower rate of ICEP relapse in
 
asthmatics treated with inhaled corticosteroids [8].
 
The development of asthma in the follow-up of ICEP
 
patients is a common finding [8]. Up to one third of the
 
patients have asthma requiring long-term corticosteroid
 
therapy after a diagnosis of ICEP has been made, and
 
some patients develop a fixed obstructive pattern on pulmonary
 
function tests [8]. Overall, more than half of
 
patients affected by ICEP may require long-term oral corticosteroid
 
therapy due to either multiple relapses or
 
severe asthma [8]. It is thus advisable to recommend
 
measures to prevent corticosteroid-induced osteoporosis
 
from the start of the treatment.


==References==
==References==

Latest revision as of 19:55, 27 March 2018

Pneumonia Main Page

Eosinophilic pneumonia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Eosinophilic pneumonia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Eosinophilic pneumonia natural history, complications, and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Eosinophilic pneumonia natural history, complications, and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Eosinophilic pneumonia natural history, complications, and prognosis

CDC onEosinophilic pneumonia natural history, complications, and prognosis

Eosinophilic pneumonia natural history, complications, and prognosis in the news

Blogs on Eosinophilic pneumonia natural history, complications, and prognosis

Directions to Hospitals Treating Eosinophilic pneumonia

Risk calculators and risk factors for Eosinophilic pneumonia natural history, complications, and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Priyamvada Singh, M.D. [2]

Overview

If left untreated, patients with eosinophilic pneumonia may progress to develop dyspnea, pleural effusion, and respiratory failure. Common complications of eosinophilic pneumonia include respiratory failure, relapse, and adverse effects of steroids. Prognosis is generally excellent, and only a couple of lethal cases have been reported.

Natural History

If left untreated, patients with eosinophilic pneumonia may progress to develop dyspnea, pleural effusion, and respiratory failure.

Complications

Prognosis

References

  1. 1.0 1.1 Philit F, Etienne-Mastroïanni B, Parrot A, Guérin C, Robert D, Cordier JF (2002). "Idiopathic acute eosinophilic pneumonia: a study of 22 patients". Am J Respir Crit Care Med. 166 (9): 1235–9. doi:10.1164/rccm.2112056. PMID 12403693.
  2. Pope-Harman AL, Davis WB, Allen ED, Christoforidis AJ, Allen JN (1996). "Acute eosinophilic pneumonia. A summary of 15 cases and review of the literature". Medicine (Baltimore). 75 (6): 334–42. PMID 8982150.
  3. Rhee CK, Min KH, Yim NY, Lee JE, Lee NR, Chung MP; et al. (2013). "Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia". Eur Respir J. 41 (2): 402–9. doi:10.1183/09031936.00221811. PMID 22599359.

Template:WH Template:WS